Compare TG Therapeutics Inc (TGTX) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Unity Software Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Unity Software Inc trades at $29.78 (market cap $13.01B). The key difference: Unity Software Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | U | |
|---|---|---|
Market Cap | $8.26B | $13.01B |
Sector | Health | Technology |
52-Week High | $59.06 | $49.47 |
52-Week Low | $26.39 | $17.13 |
Enterprise Value | $8.50B | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Unity Software (U) trades at $29.87, up 3.04% today, showing bullish technical momentum above key support levels. The company maintains strong revenue of $1.85B with improving gross margins at 62.79%, though net losses persist at -$402.77M. Recent Unity 7 platform announcements and AI integration focus signal strategic growth initiatives. Analyst consensus remains strongly bullish with 69% buy ratings and $36.50 price target, representing 22% upside potential from current levels.
Unity presents a growth opportunity with improving financial trends and strong institutional support, but faces execution risks in profitability turnaround. The stock's elevated valuation multiples (P/S 6.61, EV/EBITDA 134.62) require sustained revenue growth justification. Near-term catalyst includes Q2 2026 earnings on August 5, where analysts expect EPS of $0.24 after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
